Molecular Profile |
Indication/Tumor Type |
Response Type |
Relevant Treatment Approaches |
Therapy Name |
Approval Status |
Evidence Type |
Efficacy Evidence |
References |
KIT P577del KIT W557Lfs*5 KIT D820G
|
gastrointestinal stromal tumor
|
sensitive |
|
Cabozantinib
|
Preclinical - Pdx |
Actionable |
In a preclinical study, Cometriq (Cabometyx, cabozantinib) slowed tumor growth and decreased mitotic activity in a gastrointestinal stromal tumor patient derived xenograft (PDX) model harboring KIT mutations, P577del, W557Lfs*5, and D820G (PMID: 27777285).
|
27777285
|
KIT P577del KIT W557Lfs*5 KIT D820G
|
gastrointestinal stromal tumor
|
resistant |
|
Imatinib
|
Preclinical - Pdx |
Actionable |
In a preclinical study, a gastrointestinal stromal tumor patient derived xenograft (PDX) model harboring KIT mutations, P577del, W557Lfs*5, and D820G, demonstrated resistance to treatment with Gleevec (imatinib) (PMID: 27777285).
|
27777285
|
KIT P577del KIT W557Lfs*5 KIT D820G
|
gastrointestinal stromal tumor
|
sensitive |
|
PLX9486
|
Preclinical - Pdx |
Actionable |
In a preclinical study, PLX9486 treatment decreased Mapk and Kit downstream signaling, resulted in tumor volume stabilization in patient-derived xenograft (PDX) models of gastrointestinal stromal tumor harboring KIT P577del, W557Lfs*5, and D820G (18th Annual BSMO Meeting, Feb 2016, abstract O5).
|
detail...
|